First patient enrolled in the global, 300-patient, Phase 2 adaptive platform trial arm of RHB-107 (upamostat)1 for early COVID-19 outpatient treatment, funded through non-dilutive external sources, including the U.S. Department of Defense The study is expected to be completed by the end of 2024 RHB-107 successfully met the primary endpoint of safety and tolerability and delivered promising efficacy results, including marked reduction in hospitalization due to COVID-19 in a U.S. Phase 2 study2 RHB-107 is a novel, oral, once-daily, host-directed potential broad-acting antiviral expected to act independently of viral spike protein mutations3 RALEIGH, N.C. and TEL-AVIV, Israel, April 24, 2024 /PRNewswire/ ...

reAlpha Tech Corp. (“reAlpha”) (Nasdaq: AIRE), a real estate technology company developing and commercializing artificial intelligence (“AI”) technologies, today announced the launch of Claire, the real estate industry’s first generative AI-powered, zero-commission Smart Buyer’s Agent.

BEIJING, April 25, 2024 /PRNewswire/ -- Recon Technology, Ltd. (NASDAQ: RCON) ("Recon" or the "Company") announced today that the Company's shareholders approved on March 29, 2024 to effect a reverse stock split of the Company's Class A ordinary shares at the ratio of one-for-eighteen with the market effective date of May 1, 2024.

WestPark Capital today announced the closing of a $6,000,000 IPO for CDT Environmental Technology Investment Holdings Limited (“CDT”). CDT is a waste treatment company that designs, develops, manufactures, sells, installs, operates and maintains sewage treatment systems and provides sewage treatment services in China. The IPO consisted of 1,500,000 ordinary shares at a public offering price of $4.00 per share resulting in gross proceeds of $6,000,000, before offering expenses.